Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products for specialized medical needs. Citius Pharmaceuticals, Inc. concentrates on areas such as oncology, anti-infectives, adjunct cancer care, prescription products, and stem cell therapy. Its current portfolio includes LYMPHIR, a targeted immunotherapy for cutaneous T-cell lymphoma, along with late-stage programs such as Mino-Lok for catheter-related bloodstream infections and Halo-Lido for hemorrhoid relief. The company also advances other product candidates aimed at hospital, oncology, and acute-care settings. Headquartered in Cranford, New Jersey, Citius Pharmaceuticals, Inc. plays a role in bringing niche therapies and treatment options to patients and healthcare providers in markets with unmet clinical needs.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Leonard L. Mazur

Employees

23

Headquarters

Cranford, NJ, United States

Website

citiuspharma.com